Replies to post #82655 on Biotech Values

[genisi]

PG/NOVN 2nd gen patch for HSDD

Perhaps Intrinsa's sluggish sales in Europe and a questioning view have helped PG to put their 2nd gen patch for HSDD on hold

http://www.reuters.com/article/marketsNews/idAFL260089620090303?rpc=44

[genisi]

FWIW, I thought that PG’s will to go for a 2nd generation product, despite Intrinsa's troubles, is positive for BPAX as it provides validation of the market. So the fact that the program is "on hold" and PS doesn't talk about it, might not be a good indicator.